Delhi HC Restricts Ikra Supply In AbbVie-Zydus Patent Infringement Case
Court limits Ikra supply amid pharmaceutical patent dispute.
The Delhi High Court has temporarily restricted the supply of Zydus Lifesciences’ cancer drug Ikra following a patent infringement dispute raised by AbbVie. The court, while passing an interim order on Monday, allowed Zydus to continue manufacturing the drug but directed that no supplies of Ikra be made to Zydus or any third party from July 14 until further orders.
Justice Jyoti Singh issued the interim restriction after AbbVie approached the court alleging that Zydus’ cancer treatment product infringes its patent rights. The order will remain effective until the court hears further arguments from both parties. The court has not issued a final ruling on the patent dispute and clarified that no conclusion has been reached regarding the alleged infringement.
The dispute relates to AbbVie’s lawsuit against Zydus over the launch of Ikra, which Zydus’ counsel informed the court has been available in the market since July 2. AbbVie has claimed that the drug violates protections granted under its patent, while Zydus continues to contest the allegations in the ongoing legal proceedings.
Also Read: Four Software Professionals Die In Car Accident While Travelling To Jim Corbett Park
The High Court noted that a detailed “claim mapping” exercise would be necessary before assessing the merits of AbbVie’s claims. Claim mapping is a technical process used in patent litigation to compare the features and composition of a disputed product with the specific claims protected under a patent. The process generally requires detailed scientific and technical evaluation.
To support this examination, the court directed both AbbVie and Zydus to submit their proposed terms of reference and provide a list of experts who could assist in the claim mapping process. The exercise is expected to help the court evaluate the technical aspects of the patent dispute before making further decisions.
The matter has been scheduled for further hearing on July 24. Until then, Zydus Lifesciences can continue manufacturing Ikra, but restrictions on its supply and distribution will remain in place as the court continues to examine the issues raised in the patent infringement case.
Also Read: Fire Severely Damages Athens 2004 Olympic Badminton Hall, Roof Collapses
